What "MEA-Ready" Means (and What to Verify Before You Buy)

MEA-ready is a marketing description applied to cryopreserved neuron products, asserting that the cells will attach, survive and generate detectable extracellular electrical activity on a multielectrode array without further development work by the buyer. It is not a defined technical term, no standards body governs it, and no two vendors using it mean the same thing by it.

We searched for an indexed definition of the phrase before writing this page and found none. That absence is the reason the term is worth defining: buyers use it, vendors print it, and nothing anywhere specifies what it obliges the seller to deliver.

What the term implicitly promises

A product described as MEA-ready implies, without stating, four things:

The cells survive thaw and attach to a multielectrode array surface at a density sufficient to couple to the electrodes.
They develop spontaneous firing within a period the buyer would consider reasonable.
That firing organises into synchronised network bursts, rather than remaining as isolated uncorrelated spikes.
The behaviour is reproducible enough between lots that an experiment run in March and repeated in September gives comparable baselines.

Only the first is commonly specified on a datasheet. The other three are where projects fail, and the fourth is the one nobody guarantees.

The distinction between spiking and network bursting matters more than any other single thing on this page. A culture that fires isolated spikes on a handful of electrodes is electrically alive and experimentally close to useless for pharmacology or network work. Synchronised bursting across the array is the readout most assays actually depend on, and it arrives substantially later than first spiking — and in some cultures never arrives at all without glial support.

The seven-attribute checklist

#	Attribute	What to ask for	Why it decides the outcome	Typical vendor disclosure
1	Spontaneous activity by DIV	The days-in-vitro at which the vendor observes first detectable spontaneous spiking, and on which MEA platform	Sets your earliest possible experiment date. It is also the cheapest sanity check on arrival: if you see nothing by the stated DIV, something is wrong now rather than in six weeks	Occasionally stated as a range in an application note. Rarely on the datasheet, rarely as a specification
2	Network bursting behaviour	The DIV at which synchronised network bursts appear, with a definition of the burst detection criterion used	This, not spiking, is the functional endpoint for most assays. Published MEA work on iPSC neurons commonly runs cultures for three weeks or more before pharmacology; longer for 3D formats	Usually shown as a representative figure, not a specification. Almost never with the burst detection parameters
3	Coating requirement	The exact substrate, concentration, incubation time and whether the vendor’s stated performance was obtained on that coating	Coating is the single most common cause of a failed first MEA run. Poly-ornithine/laminin and PEI/laminin are not interchangeable, and MEA surfaces coat differently from tissue-culture plastic	Generally stated in the protocol. Concentrations and timings sometimes differ between the datasheet and the user guide — follow the user guide
4	Co-culture requirement (astrocytes)	Whether the vendor’s activity data was generated with or without astrocytes, and at what ratio	Astrocyte co-culture is routinely used in published iPSC-neuron MEA work. A vendor whose traces were recorded in co-culture is showing you the performance of a two-product system while selling you one product	Sometimes disclosed in the figure legend. This is the disclosure most often buried
5	Seeding density	Cells per well or per square millimetre for the specific MEA plate format, and whether it is a spot/droplet or whole-well seeding	Density drives coupling, and the working range is narrow. Too sparse and you get no network; too dense and you get detachment. Density also directly sets how many vials you must buy, so it is a cost question as well as a technical one	Usually stated for the vendor’s own reference format only, which may not be your plate
6	Plate compatibility	Confirmation on your specific MEA hardware — for example Axion Maestro, MaxWell MaxTwo, Multi Channel Systems — and your specific well count	Electrode geometry, well area and recording modality differ enough between platforms that a density and coating validated on one is a starting point, not a transfer	Named platform validation is uncommon. Ask which platform generated the figures
7	Published raw traces	Raw or minimally processed recordings, or at minimum spike raster plots with axes and n, rather than a summary bar chart	This is the honesty test. Summary statistics can be produced from a culture that would not support your assay. Rasters cannot hide the absence of network structure	Rare. A vendor who publishes rasters and lot-to-lot comparisons is disclosing something the market does not require them to disclose

How to read attribute 4 in particular

Take the astrocyte question seriously, because it is where the cost model moves.

Published MEA work on human iPSC-derived neurons routinely includes iPSC-derived astrocytes as a co-culture partner, and vendor-authored posters describe recordings from neurons cultured “alone or in combination with human iPSC-derived astrocytes.” If a product’s headline network activity figure was generated in co-culture, then buying the neuron alone buys you an input to the experiment, not the experiment.

The commercial consequence is straightforward. Astrocyte SKUs are priced comparably to neuron SKUs, and they are frequently sold by a different vendor with a different medium. A neuron budget that has not accounted for the glial partner can be out by a factor approaching two, and the two products may not have been validated together by anyone.

What MEA-ready does not mean

It does not mean plated. Almost every product sold as MEA-ready arrives as a frozen vial. You do the thawing, the coating, the seeding, and the four-to-eight-week maturation. The maturation period is where most of the risk and most of the labour sits, and it is entirely on the buyer.

It does not mean an activity guarantee. We are not aware of any vendor selling cryopreserved neurons against a numerical activity acceptance criterion — for example, a stated mean firing rate or a stated proportion of active electrodes by a stated DIV, with a remedy if the delivered lot misses it. Post-thaw viability is specified. Electrical function is illustrated.

It does not mean lot-to-lot equivalence. Two lots of the same catalogue number can mature on different timelines. If your experiment spans lots, plan a bridging comparison and budget for it.

It does not mean your platform. See attribute 6.

Boundary cases

Is a neural progenitor product MEA-ready? No, and it should not be described that way. NPCs require an in-house differentiation step before any electrophysiology, which moves the timeline out by weeks and the risk onto you. They can be an excellent purchase — they are expandable, which changes the economics for repeated work — but the term does not apply.

Are cardiomyocytes MEA-ready? They are commonly run on MEA and field-potential platforms, and they are spontaneously active within days of plating rather than weeks, which is why they are a much easier first contractile or electrically active culture than neurons. But the assays, the endpoints and the analysis are different enough that vendors and platforms treat cardiac MEA as its own category.

Is an organoid or a 3D culture MEA-ready? Only against a 3D-capable array or a dedicated 3D MEA. Published 3D hiPSC neural network work on MEA describes maturation followed over roughly six and a half weeks, which is a different planning horizon from a 2D monolayer.

What about “assay-ready”? A separate and stronger claim, usually meaning the cells arrive already plated in a specified format. If a supplier will deliver a plated, matured, already-firing culture against a written activity criterion, that is a materially different product from a frozen vial and should be priced and contracted as one.

The question that resolves it

If you ask a supplier one question about an MEA-ready claim, ask this:

On which MEA platform, at what seeding density, on what coating, with or without astrocytes, at what DIV did you record the traces in your marketing material — and will you send me the raw recording?

Every attribute in the table is contained in that question. Suppliers with a real product answer it in a paragraph. The answer, or the absence of one, tells you what you are buying before you spend six weeks finding out at the bench.

MEA-ready: definition, and the seven things to verify